| INTRODUCTION
Hearing loss affects 12% of individuals over the age of 12, or around 30 million Americans (NIDCD, 2010) . The likelihood of having bilateral hearing loss doubles each decade after the age of 50 (Bainbridge & Wallhagen, 2014) , to the point that over 60% of people aged 70 or older have hearing loss (Lin, Thorpe, Gordon-Salant, & Ferrucci, 2011) . Outer hair cell loss is a significant factor in many kinds of hearing loss (Crowe, Guild, & Polvogt, 1934; McGill & Schuknecht, 1976) , largely because these specialized acoustic amplifying cells do not regenerate their numbers if they die (Chardin & Romand, 1995) . The goal of this work is to test a candidate signaling pathway for its ability to drive the early cellular activities of cochlear regeneration: proliferation of supporting cells and their trans-differentiation into hair cells (Brignull, Raible, & Stone, 2009; Corwin & Cotanche, 1988; Ryals & Rubel, 1988) , with an emphasis on outer hair cell trans-differentiation.
Ligands and receptors from the epidermal growth factor (EGF) family were implicated in mouse utricular supporting cell proliferation in early experiments (Hume, Kirkegaard, & Oesterle, 2003; Kuntz & Oesterle, 1998) . In other epithelial organs, members of the epidermal growth factor receptor (EGFR) family can be activated through tissue stretch damage to induce proliferation (Vermeer et al., 2003) , making this signaling pathway an attractive candidate for sensing acoustic injury in the cochlea. In vitro, EGF promotes hair cell differentiation from dissociated embryonic cochlear precursors (Doetzlhofer, White, Johnson, Segil, & Groves, 2004) and promotes the proliferation of dissociated mouse cochlear supporting cells (White, Stone, Groves, & Segil, 2012) . Moreover, the avian auditory supporting cells require signaling from the EGFR family for proliferation in regeneration experiments in vitro (White et al., 2012) . Other experiments have implicated canonical downstream signaling molecules of the EGFR family such as PI3K (Montcouquiol & Corwin, 2001 ). However, there are no reports that adding exogenous EGF family ligands affects proliferation in mouse cochlear organ cultures. Thus, it is unclear what role, if any, that signaling from the EGFR family may play in stimulating the cellular activities of cochlear regeneration.
To test the hypothesis that signaling through the EGFR family can effect either proliferation or hair cell differentiation in supporting cells, we use multiple tools to drive such signaling in mouse cochlear supporting cells. First, we generated a custom adenovirus that drives expression of a mutated member of the EGFR family, ERBB2, with constitutive activity (CA-ERBB2). We used this virus to infect neonatal mouse cochleae in vitro. We assayed these cultures for supporting cell marker expression and proliferation. Second, we used a tetracycline inducible transgene (TET-ON), also encoding a constitutively active ERBB2 receptor, to promote signal transduction in neonatal mouse supporting cells in vivo. We assayed these mice for supporting cell marker expression, proliferation, and supernumerary hair cell marker expression. Finally, we tested two small molecules that activate signaling from a second member from the EGFR family, ERBB3 Swoboda et al., 2013) , on neonatal mouse cochlear cultures. These cultures were then assayed for supporting cell proliferation and hair cell marker expression in neonatal mouse cochlear cultures.
| MATERIALS AND METHODS

| Mice
The following mouse strains were used. Fgfr3-iCre (Cox, Liu, Lagarde, & Zuo, 2012 ) was a kind gift from Dr. Jian Zuo. CD1 mice, Atoh1-GFP (Lumpkin et al., 2003) , CA-ErbB2 (Xie, Chow, Paterson, Chin, & Kudlow, 1999) , ROSA-floxed-rtTA/ GFP (Belteki et al., 2005) , ROSA-floxed-tdTOMATO (Ai14, (Madisen et al., 2010) , and Sox2-CreER (Suh et al., 2007) were all purchased from Jackson Laboratories. Crosses between Fgfr3-iCre, ROSA-floxed-rtTA/GFP, and CA-ErbB2, and crosses between Sox2-CreER, ROSA-floxed-rtTA/GFP, and CA-ErbB2 mice were used for in vivo experiments. Crosses between Sox2-CreER and ROSA-floxed-tdTOMATO were used for Sox2-lineage tracing in vitro experiments. Finally, unmodified CD1 mice and Atoh1-GFP mice were used for the remaining in vitro experiments. In all, 171 mice were euthanized in the course of these experiments, including transgenic littermates that were not used for controls.
The University Committee for Animal Resources (UCAR) approved all mouse experiments at the University of Rochester, and the Massachusetts Eye and Ear Infirmary Institutional Animal Care and Use Committees (IACUC) approved all mouse experiments at the MEEI. Both male and female mice were used equally throughout these experiments. Mice were maintained on a 12 hr light-dark cycle, housed not more than five adults per cage with food and water available ad libitum. Mice also received ample nesting supplies and small houses. The day that pups were found was designated P0. Genotyping primers and protocols are available upon request.
| Administration of substances to mice
Substances were administered to genetically modified mice, in order to activate gene expression and label dividing cells for in vivo experiments only. This includes doxycycline food (200 mg/kg of chow, BioServ #S3888), which replaced the dam's normal chow. In addition, three substances were administered via injections to post-natal day 0 to post-natal day 2 (P0-P2) pups intramuscularly, in the upper thigh, using Ultrafine insulin syringes (Becton-Dickinson 31G #08290-328468). These included doxycycline hyclate (DOX: 100 mg/kg body weight, Sigma Aldrich #D9891), which was freshly prepared as 10 mg/ml stock in 0.9% sterile saline. 5-ethynyl-2′-deoxyuridine (EdU: 0.01 mg/kg, Invitrogen #A10044) was made as a 10 mM stock solution in DMSO and diluted for injection to 40% strength in 0.9% sterile saline. Tamoxifen (75 mg/kg, Sigma, #T5648) was dissolved in corn oil (Sigma, #C8267) at 5 mg/kg.
| Antibodies
The following antibodies were used: ERBB2 (Neu C-18, rabbit polyclonal, Santa Cruz Biotechnology #SC284); phosphor-ERBB2 (P-Neu Try1248, rabbit polyclonal, Santa Cruz #SC12352); phosphor-PI3K (P-PI3-Kinase P85α, rabbit polyclonal, Santa Cruz #SC12929); β-ACTIN (BA3R, mouse monoclonal, ThermoFisher Scientific #MA5-15739); SOX2 (Y-17, goat polyclonal, Santa Cruz #SC17320); MYO7A (H-60, rabbit polyclonal, Santa Cruz #SC25834); JAG1 (C-20, goat polyclonal, Santa Cruz #SC6011); GFP (chicken polyclonal, Abcam, ab13970); RFP (rabbit polyclonal, Rockland #600-401-379); OCM (goat polyclonal, N-19, Santa Cruz #SC7446); PVALB (mouse monoclonal, EMD Millipore #MAB1572). Secondary antibodies were purchased from Jackson Immunoresearch. We used fluorescently conjugated donkey secondaries and horseradish peroxidase (HRP) conjugated goat secondaries.
| Western blotting
To obtain fibrocytes, P3 mouse brains were minced in Dulbecco's Modified Essential Media with Glutamax (DMEM, Gibco, #10569-044), trypsinized (0.25% trypsin/ EDTA, Gibco, #25200056) for 3 min at 37°C, neutralized with 10% fetal bovine serum (FBS, Hyclone #SH30088) in DMEM, triturated, filtered through a 40 μm nylon mesh (Falcon cell strainers, #352340), and plated on uncoated plates in DMEM Glutamax, with 10% FBS, 1% penicillin and streptomycin supplement (Gibco #15140122), and 25 mM HEPES (Gibco #15630080). Cultures were fed every 2 days. After reaching confluency (around 6-7 days), the cells were re-plated in 6-well plates at 10 6 cells/well.
To assay adenovirus activity, wild-type fibrocytes were infected for 24 hr and then extracted in RIPA buffer (10 mM Tris, 100 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X100, 100 μg/ml phenylmethylsulfonyl fluoride) supplemented with HALT protease and phosphatase inhibitors (Thermo Scientific, #78430 & #78420, respectively).
To assay transgene activity, fibrocytes were isolated from transgenic mice, and cultured similarly. They were stimulated with freshly prepared 2 μg/ml DOX (Fisher, #BP2653) prior to extraction in RIPA buffer with HALT protease and phosphatase inhibitors. Extracts were sonicated and quantified (Micro BCA Protein Assay Kit, Thermo, #23235). A 20 μg of protein per lane were boiled with Laemmli buffer, subjected to polyacrylamide gel electrophoresis/PAGE (12% Mini PROTEAN Gels, BioRad, #4561043), and transferred to a nitrocellulose membrane (Sigma, GE #10600016) using ice cold transfer buffer (25 mM Tris base, 200 mM glycine, and 25% methanol). Blots were probed with primary antibodies (1:1,000) in Tris-buffered saline (TBST, 10 mM Tris, 150 mM NaCl) at pH 7.5, with 0.5% Tween-20 and 5% nonfat milk, overnight at 4°C. Secondary antibodies (anti-mouse and anti-rabbit, Jackson Immunoresearch, #115-035-003 and #111-035-003) conjugated with HRP were further incubated with the blot in the same buffer for 1 hr at room temperature. Signal was revealed with SuperSignal West Pico Chemiluminescence Substrate (Thermo Scientific, #34087) and X-ray film (Kodak BioMax, #829-4985).
| Tissue processing
P8 and P14 mice were euthanized with carbon dioxide and decapitated, and P2-P3 pups were decapitated. Inner ears were fixed at least overnight in 4% paraformaldehyde in phosphate buffered saline (PBS, pH 7.4) at 4°C. P8 and P14 inner ears were further decalcified for 3 days in 100 mM EDTA. For sectioning, inner ears were cryoprotected in 30% sucrose, embedded in OCT compound (Andwin Scientific #25608930), frozen in liquid nitrogen, and sectioned at 20 μm onto Superfrost Plus slides (Fisher, . For whole mount, P8 and P14 cochleae, fixed and decalcified as described above, were dissected into three large pieces (Montgomery & Cox, 2016 ).
| Construction of the ErbB2 adenoviruses
Plasmid #16259 (human HER2, V654E) and plasmid #16258 (human HER2, K753M) were purchased from Addgene and sequenced. Both plasmids were originally in the vector pcDNA3 with 5′ and 3′ HindIII cloning sites. They were cloned into the HindIII site of pAdTrack-CMV (He et al., 1998) . These constructs were recombined with pAdEasy in BJ5183 competent cells (Agilent Technologies). Subsequently, Adenovirus5 (Ad5) was produced and titrated using standard methods. Western blot experiments were used to verify the activity of the constructs, as described in the Results section. The GFP virus was purchased from Vector Biolabs. All viral protocols were reviewed by the URMC Biosafety committee to ensure the safety of staff members and the environment.
| Cochlear culture and infection
P1-P2 pups were decapitated and their cochleae dissected into DMEM/F12 media (Gibco 11330-032) buffered with 15 mM HEPES (Gibco, 15630-080) . Cochleae were cultured on Lab-Tek CC2 chamber slides (Nunc 154917) coated with 0.5 mg/ml poly-D-lysine (Sigma P6407) and 2 μg bovine fibronectin (Sigma F1141). After removal of the tectorial membrane, the apical and basal turns were cut away to obtain the middle turn. These were placed in the slide wells with a minimal amount of media and incubated for 10 min at 37°C in 5% CO 2 to facilitate attachment. Middle turns were cultured overnight in DMEM/ F12 with 15 mM HEPES, 1 mg/ml penicillin G (Sigma P3032), 2% B27 supplement (Gibco 17504-044), 25 ng/ml EGF (Sigma E1257), and 1% FBS (HyClone SH30088). The next day, the media were replaced with similar culture media, except that it now lacked FBS and contained 2 μM EdU (Invitrogen A10044). Note that in other studies, the higher concentrations of EdU have been associated with DNA damage in various stem cell types (Kohlmeier, Maya-Mendoza, & Jackson, 2013) . In preliminary experiments, we found that the inclusion of 1% FBS facilitated organ attachment, but its presence during adenovirus infection increased the basal level of supporting cell proliferation. Middle turns were infected with 1-3 x10 7 particles per 500 μl culture in a dedicated virus lab using BSL2+ precautions. For Sox2-Cre lineage tracing, 10 μM (z)-4-hydroxytamoxifen (Sigma H7904) was added on the day of isolation to stimulate CRE activity. All viral procedures were reviewed and approved by the University of Rochester's Institutional Biological Safety Committee. After incubations, cultures were fixed overnight in fresh 4% paraformaldehyde in PBS at 4°C.
| Immunostaining
Sections were dried at 50°C prior to staining. For cochlear cultures on LabTek chamber slides, the wells were removed prior to staining without drying. Both sections and cultures were stained with identical procedures. They were first washed three times in PBS (Gibco, 14190-144) at room temperature for 10 min each. If the analysis involved the assessment of proliferating cells by EdU incorporation, the EdU Click-It kit (Invitrogen C10339 or C10340) was used next. This reaction was performed prior to antibody staining according to the manufacturer's instructions. Then sections and cultures were both blocked with 5% donkey serum in PBS with 0.5% Triton X100 for 1 hr at room temperature, and incubated overnight in block containing primary antibodies diluted to 1:500 at 4°C. After the primary incubation, they were washed three times in PBS for 10 min each, and then were incubated for 2 hr in secondary antibodies diluted to 1:500 at room temperature. After the secondary incubation, sections and cultures were washed three times in PBS for 10 min each and mounted in ProLong Gold (Invitrogen #P36930). Whole mount cochlear tissue was first washed three times in PBS at room temperature for 20 min each with gentle rocking. Next, the EdU Click-It kit was used according to the manufacturer's instructions. The tissue was then boiled in 10 mM citric acid (pH 6.0) for 15 min in a microwave on low power, allowed to cool slowly to room temperature for 1 hr, washed three times in PBS at room temperature for 20 min each with gentle rocking, and blocked with 5% donkey serum in PBS with 0.5% Triton X100 for 1 hr at room temperature with gentle rocking. Tissue was then incubated overnight in block containing primary antibodies diluted to 1:500 at 4°C. After the primary incubation, tissue was washed three times in PBS for 20 min each, and then incubated for overnight in secondary antibodies diluted to 1:500 at at 4°C. After the secondary incubation, sections and cultures were washed three times in PBS for 20 min each. Tissue was mounted in ProLong Gold (Invitrogen #P36930) between two 50 mm long coverslips, using two 25 mm square coverslips at either side to make a small well for the mounting medium.
| Cochlear culture with Pa2 g4/ EBP1 inhibitors
Cochleae were isolated from post-natal day 1-day 2 wild-type or Atoh1-nGFP mice (Lumpkin et al., 2003) . The organ of Corti was isolated from the otic capsule, and the nerve tissue and stria vascularis were removed. The organ of Corti was plated on a glass coverslip coated with a 1:10 mixture of Matrigel and DMEM/F12 to promote attachment. Cochlear explants were cultured in a serum-free 1:1 mixture of DMEM and F12, supplemented with Glutamax, N2, and B27. For the treated cochlea, small molecules were added to this culture medium, while the control cochlea was cultured with medium containing DMSO at the same concentration used in the treatments. To measure proliferation, explants were treated with EdU (10 μg/ml) along with the drug or DMSO. Drug-treated explants were cultured for 3 days then fixed in 4% paraformaldehyde for 30 min.
| Confocal microscopy and image analysis
All imaging was done on an Olympus FV1000 laser scanning confocal microscope using the Fluoview software package. imagej 64 (NIH) was used to Z-project maximal brightness in confocal stacks. Photoshop (Adobe) was used to set maximal and background levels of projections for the construction of figures.
| Experimental design and statistical analysis
Data fields were blinded and randomized using a deck of cards prior to quantification. Virally infected cochleae were imaged at 20× on a confocal microscope using the stitching function of the FV1000 to obtain a composite of the entire field (3,000 px by 3,000 px). With only the supporting cell marker channel visible, one individual positioned 200 μm rectangles along the supporting cell region (usually 5-7 per middle turn) and then used the channel as a mask to reveal EdU+ cells. The rectangles were cropped out of the original images, exported as TIFs, and renamed using a deck of cards. Another individual blinded to condition counted the EdU+ cells. After unblinding, the rectangles were averaged to obtain a biological replicate and the average of these replicates is presented in the text.For EdU+ and MYO7+ cells in P8 and P14 confocal stacks, an individual blinded to genotype counted EdU+ nuclei and supernumerary MYO7+ cells in P8 and P14 Fgfr3-iCre/CA-ErbB2 image files by examining stack side views. ANOVA was used to establish statistical significance for data groups and a Student's two-tailed t test with Bonferroni correction was used to establish pair-wise significance.
To quantify WS3 and WS6-treated cochleae, the length of the sensory epithelium was measured using imagej software with the overall length determined from the hook to the apex in each sample. The number of myosin VIIa-positive cells or Edu positive cells in the supporting cell region was manually counted. The total number of cells was counted in each of the four cochlear segments of 1,200-1,400 μm (apical, midapical, mid-basal, and basal), density (cells per 100 μm) was then calculated for each segment. Statistical analyses were performed using prism version 7.0 software, comparisons among groups were made by one-way ANOVA followed by Dunnett's multiple-comparisons test for comparing the mean of each group with the mean of a control group.
| RESULTS
| In vitro, CA-ERBB2 drives cochlear supporting cell proliferation in a non-cell autonomous manner that correlates with the down-regulation of SOX2
To determine if supporting cells with active ERBB2 signaling proliferate, we constructed adenoviruses to drive expression F I G U R E 1 Viral CA-ERBB2 transduction drives ERBB2 phosphorylation and downstream signaling. (a) A schematic of CA-ERBB2 receptors shows the mechanism of dimerization. The asterisk indicates approximate region of mutation, where a valine is transformed to a glutamine in the transmembrane domain. This alteration drives constitutive interactions between receptors and subsequently kinase activity in the absence of ligand. (b-e) Mouse brain fibrocytes were isolated from control mice and separately infected with three viral constructs, GFP (1), I-ErbB2 (2), and CA-ErbB2 (3) for 24 hr. Their protein extracts were analyzed in Western blots with antibodies against ERBB2 (b), phosphor-ERBB2 (c), phosphor-PI3Kreg (regulatory unit of PI3K) (d), and β-ACTIN (e). β-ACTIN was used as a loading control. All four panels were processed at the same time and exposed together. ERBB2 protein has an approximate size of 190 kDa, PI3Kreg has an approximate size of 185 kDa, and β-ACTIN has an approximate size of 42 kDa. Only CA-ErbB2 infected fibrocytes demonstrate activation of both downstream phosphorylation events. (f) Semi-quantitation of Western blots (imagej). Values for GFP (circles), I-ErbB2 (triangles), and CA-ErbB2 (squares) are shown. The y axis shows arbitrary units of mutated ERBB2 in conjunction with GFP. In many human cancers, mutated HER2/ERBB2 harbours a charged glutamic acid residue in place of a hydrophobic valine located in the transmembrane region (Figure 1a, asterisk) . This glutamic acid facilitates the dimerization of mutated ERBB2 polypeptides, enabling phosphorylation of intracellular tyrosine residues (Stern, Kamps, & Cao, 1988; Weiner et al., 1989) and activation of the downstream effector PI3K via sub-unit phosphorylation (p185/ PI3Kr). In previous studies regarding supporting cell proliferation after dissociation, inhibitors of PI3K blocked BrdU incorporation in a dose-dependent fashion (White et al., 2012) . We used two ErbB2 constructs derived from human cancer studies (Li et al., 2004) : CA-ErbB2, containing this activating mutation, and I-ErbB2, in which the valine is instead mutated to isoleucine; this mutation fails to drive auto-phosphorylation. We tested both constructs, along with a GFP-only control, in fibrocyte culture by Western blot (Figure 1b-e) . While ERBB2 immunoreactivity was detected in culture extracts infected with either virus (Figure 1b , α-ERBB2), downstream events such as phosphorylation of ERBB2 or the PI3K regulatory unit were only observed consequent to CA-ErbB2 infection (Figure 1c ,d, α-pERBB2 and α-pPI3Kreg). Semi-quantitative analysis of the blots illustrates the profound increase in downstream signaling for CA-ERBB2 (Figure 1f , green) compared to I-ERBB2 (Figure 1f , red, around 6-fold for pERBB2 and 40-fold for pPI3K) and GFP (Figure 1f , blue, around 30-fold for pERBB2 and 1,000-fold for pPI3K).
We infected cultures of neonatal cochlear middle turns with the three adenoviruses. Twenty-four hours later, we assayed proliferation by EdU incorporation (Figure 2 , white). In previous experiments, 24 hr was sufficient for dissociated supporting cells to re-enter the cell cycle but not long enough for them to complete more than one cycle (White et al., 2012) . As a consequence, counting cells at 24 hr does not overestimate the occurrence of cell cycle re-entry. Infected cells expressed GFP (Figure 2, green) , and anti-JAG1 (Figure 2a ,c,e, red) was used to label supporting cells. EdU incorporation was focal, and it was not evenly distributed through the organ (Figure 2e ). To avoid field selection bias, we quantified proliferation in these middle turn cultures from stitched confocal images, positioning 200 μm long rectangles on these images with only the JAG1 channel visible. A schematic of this strategy is shown in Figure 2g , where rectangles indicate F I G U R E 2 Viral CA-ERBB2 transduction in P2 cochlear cultures drives non-cell autonomous proliferation in JAG1+ supporting cells, but not in cells that maintain SOX2 expression. P2 cochlear middle turns were infected in vitro by each of the three viruses: GFP (a, b), I-ErbB2 (c, d), and CA-ErbB2 (e, f). Antibodies against JAG1 (a, c, e, red) and SOX2 (b, d, f, cyan) are used to identify supporting cells. Staining of GFP (green) and EdU (white) reveal infected and proliferating cells, respectively. Similar numbers of JAG1+/EdU+ cells were seen in GFP-infected and I-ErbB2 infected cultures (T GFP = 39.5, T I = 37.6, p = 0.89, n GFP = 8, n I = 6, two-tailed t test), but significantly more were seen after CA-ERBB2 infection (T GFP = 39.5, T CA = 72.9, p = 0.04, n GFP = 8, n CA = 10, two-tailed t test). However, few SOX2+/EdU+ nuclei are observed in a similar region of the cochlea (cf. e and f). Scale bar: 200 μm. To quantify these explants without bias, the whole organ was imaged at 20× using the confocal "stitching" function (g, blue) and closely situated rectangles representing 200 μm (g, grey) were used to crop fields for blinded, randomized counting. [Colour figure can be viewed at wileyonlinelibrary.com]
example fields cropped from a large, stitched image for quantification. We then blinded and randomized the resulting sections of EdU+ cells revealed through the JAG1 mask. Increased proliferation was observed in CA-ErbB2-infected cultures. The overall results, expressed as EdU+ cells/mm, were modest, but significant (F = 3.8, T GFP = 39.5, T I = 37.6, T CA = 72.9, p = 0.040, n = 24, ANOVA). Proliferation within the JAG1+ supporting cell region did not differ between GFP-infected and I-ErbB2 infected cultures (T GFP = 39.5, T I = 37.6, p = 0.89, n GFP = 8, n I = 6, two-tailed t test). However, a significant increase in EdU incorporation was observed in the supporting cell region marked by anti-JAG1 after CA-ErbB2 infection compared to GFP only (T GFP = 39.5, T CA = 72.9, p = 0.04, n GFP = 8, n CA = 10, two-tailed t test).
Since virally infected cells express the lineage tracer GFP, we examined images of these cultures to determine if infected cells proliferate (Figure 2e) . Surprisingly, EdU incorporation (Figure 2e , red) was observed in the supporting cell region in the cells adjacent to the CA-ErbB2 infected cells (Figure 2e, green) , indicating a non-cell autonomous effect. We replicated these experiments using anti-SOX2 to mark the supporting cells (Figure 2b, D, F, cyan) . Remarkably, co-localization of EdU with SOX2 was rarely observed in cultures infected with CA-ErbB2 (Figure 2f, cf. white and  cyan) .
With the lack of co-localization between EdU+ and SOX2+ cells, we wondered if SOX2 protein is downregulated in supporting cells when they begin mitosis. Previous studies have implicated SOX2 in the regulation of Cdkn1b in cochlear supporting cells . In order to determine if these in vitro proliferating cells were originally SOX2+, we crossed a Sox2-CreER knock-in line to a ROSA-floxed tdTomato line and used the progeny for infection experiments. We induced Td-TOMATO (TOM) expression with 4-hydroxytamoxifen in culture prior to viral infection (Figure 3 ). Cultures were assayed for infection, marked by GFP (green staining, pink arrows), Sox2-lineage TOM expression (red staining), SOX2 protein expression (cyan staining), and EdU incorporation (white staining, yellow arrows). Little proliferation was observed in the GFPinfected cochleae at 24 hr (Figure 3a , white). Consistent with previous experiments, we observed non-cell autonomous proliferation from CA-ERBB2 infection; e.g. EdU+ cells are GFP-negative (Figure 3c, cf. 3C', yellow arrows, cf. white and cyan, n = 566 total cells). These cells are in the TOM+ region (Figure 3c , cf. white nuclei with red cell bodies). EdU+/SOX2-nuclei were interspersed in the SOX2+ nuclear layer at 32 hr after infection (Figure 4d ). These data are consistent with a downregulation of SOX2 as proliferation was initiated in cochlear supporting cells.
| Constitutively activated ERBB2
does not promote cochlear supporting cell proliferation in vivo constitutively active rat ERBB2 protein, which harbours the same valine to glutamic acid mutation used previously (Xie et al., 1999) . We validated the CA-ErbB2 transgene in protein extracts from cultures of fibrocytes derived from mice harbouring both a CA-ErbB2 transgene and a functional ROSA-rtTA knock-in gene ( Figure 4a , lanes a), comparing them to extracts isolated from fibrocyte cultures with ROSArtTA alone (Figure 4a , lanes b). Twenty-four hours after doxycycline (DOX) addition, ERBB2 protein was evident on Western blots (Figure 4a , α-ERBB2, cf. lanes a and b). Both ERBB2 and the regulatory unit of PI3K were phosphorylated (Figure 4a , α-pERBB2, α-pPI3K, cf. lanes a and b). Probing with anti-β-ACTIN revealed similar protein amounts in both extracts (Figure 4a , α-β-ACTIN, cf. lanes a and b). To determine the onset of PI3K phosphorylation, we harvested sister cultures from CA-ErbB2/ROSA-rtTA derived fibrocytes at 2, 4, 6, and 8 hr after DOX addition. Phosphorylation of the PI3K regulatory unit was evident at 8 hr (Figure 4b ). These data indicate that expression of the CA-ErbB2 transgene indeed resulted in phosphorylation of ERBB2 and its downstream target, PI3K.
To express CA-ERBB2 in cochlear supporting cells, we used the Fgfr3-iCre knock-in to activate a floxed ROSA-rtTA/ GFP knock-in gene in supporting cells in neonatal CA-ErbbB2 mice (Figure 4c , (Cox et al., 2012) ). All mice shown for these experiments harbour the floxed ROSA-rtTA-GFP knock-in gene. The injection schedule for inducing CA-ERBB2 and labeling proliferating cells is shown in Figure 4f . Cochleae from pups sacrificed at P3 were analyzed for p-ERBB2 immunoreactivity (Figure 4d , E, red) and GFP expression (Figure 4d , E, green). The co-localization of GFP and p-ERBB2 was readily apparent in animals harbouring both Sox2-CreERT and CA-ErbB2 (note Figure 4d′, inset) . At this time point, we found that in Sox2-CreERT triple transgenic mice, 96% of GFP+ cells also expressed p-ERBB2, and 98% of p-ERBB2+ cells also expressed GFP (n = 281 cells). Similarly, in Fgfr3-iCre triple transgenic mice 96% of GFP+ cells also express p-ERBB2 and 89% of p-ERBB2+ cells also express GFP (n = 172 cells).
Since SOX2 protein was not detected in most supporting cells as they re-entered the cell cycle, we examined SOX2 protein by immunofluorescence in mice that harboured either Sox2-CreERT or Fgfr3-iCre in addition to Ca-ErbB2 and ROSA-flox-rtTA-GFP modifications. Exposure-matched images of p-ERBB2 (Figure 4g -i, red) and SOX2 protein (Figure 4g-i, cyan) show an apparent reduction in the numbers of SOX2+ cells when compared to control CA-ErbB2/ ROSA-flox-rtTA-GFP mice alone. Per 200 μm segment, control organs contained significantly more SOX2+ cells compared to both CA-ERBB2-expressing genotypes (F = 5.9, T con = 212, T Sox2 = 74, T Fgfr3 = 49, p = 0.013, n = 6 blinded fields per genotype, ANOVA).
Using the treatment schedule illustrated in Figure 4f , we tested if supporting cells proliferated in vivo after CA-ERBB2 induction ( Figure 5 ). We co-labeled cochleae from each of the three genotypes for SOX2 (Figure 5a-c, cyan) , EdU (Figure 5a-c, white) , and p-ERBB2 (Figure 5a-c,  red) . EdU+ nuclei were clustered in and near cells containing phosphorylated ERBB2 (Figure 5b ,c, cf. red and white). We assessed the numbers of EdU+ cells at P8 and P14, using blinded confocal stacks (Figure 5d ) labeled for DAPI (blue), GFP (green), EdU (red), and MYO7 (white). No significant differences were seen in the numbers of EdU+ cells/mm at either P8 (T con = 21.0, T CA = 21.9, p = 0.88, n = 4 per genotype, student's two-tailed t test) or P14 (T con = 8.6, T CA = 12.5, p = 0.065, n = 3 per genotype,
F I G U R E 4 Activation of CA-ERBB2 in cochlear supporting cells at neonatal stages drives SOX2 down-regulation in vivo. (a) Western analysis
of lysates obtained from brain fibrocytes from ROSA-rtTA+/CA-ErbB2+ mice (lane a) and ROSA-rtTA mice (lane b) cultured for 24 hr after DOX addition, which stimulates the production of the CA-ERBB2 protein. Antibodies specific for ERBB2, phosphor-ERBB2, β-actin, and phosphorPI3Kreg proteins (clockwise from upper left) were used to probe blots made with the two lysates. β-ACTIN serves as a loading control. L indicates the molecular weight ladder run on the blot. All four panels were run at the same time and exposed together. ERBB2 protein has an approximate size of 190 kDa, PI3Kreg has an approximate size of 185 kDa, and β-ACTIN has an approximate size of 42 kDa. Only ROSA-rtTA+/CA-ErbB2 fibrocytes demonstrate activation of both downstream phosphorylation events. (b) Western analysis of CA-ErbB2 protein induction. Only CA-ErbB2/ROSA-rtTA derived fibrocytes are shown. Samples were harvested 2, 4, 6, and 8 hr after DOX addition and probed with the same four antibodies as (a). Antiphosphor-PI3Kreg signal is evident at 8 hr. (c) Example breeding scheme used to generate mice for these experiments. Fgfr3-iCre is shown; Sox2-CreERT mice were similarly bred. A red X is placed over symbols for genes if the protein cannot be expressed in that genetic combination. Only mice harbouring all three modifications can express CA-ERBB2. Note that the ROSA-flox-rtTA modification includes an IRES-GFP (not shown), which enables lineage tracing of cells where that locus is recombined after CRE activation. (d, e) GFP produced along with TA protein from the ROSA locus (green) co-localizes with p-ERBB2 in mice harbouring both Sox2-CreERT, CA-ErbB2, and ROSA-flox-rtTA genes (d, red) but not CA-ErbB2 and ROSA-flox-rtTA alone (e, red). Inset in d′ shows co-localization. Scale bar: 20 μm. Anti-phosphor-ERBB2 staining confirms that CA-ERBB2 is active in GFP+ supporting cells. (f) A schematic of experimental design depicts the timing of tamoxifen (amber), DOX (pink), and EdU (black) injections into pups. EdU analysis is presented in Figure 5 . (g-i) Mice harbouring CA-ErbB2 (g), Sox2-CreERT/CaErbB2 (h), and Fgfr3-iCre/CA-ErbB2 (i), in conjunction with the ROSA-flox-rtTA modification, were treated as shown in (f). P3 cochleae were isolated and analyzed for phosphor-ERBB2 (red) and SOX2 protein (cyan). SOX2+ cells were significantly reduced in number after CA-ERBB2 activation: Per 200 μm segment, control organs (g) contained significantly more SOX2+ cells compared to both CA-ERBB2-expressing genotypes (F = 5.9, T con = 212, T Sox2 = 74, T Fgfr3 = 49, p = 0.013, n = 6 per genotype, ANOVA). Scale bar 100 μm. [Colour figure can be viewed at wileyonlinelibrary.com] | ZHANG et Al. student's two-tailed t test), indicating that the activation of CA-ERBB2 is not sufficient to drive significant increases in proliferation in vivo.
Although approximately one in four pups analyzed at P3 or P8 harboured both Fgfr3-iCre and CA-ErbB2, we obtained only three in 34 mice at P14. Similar experiments performed with Sox2-CreERT mice yielded no mice with both a Cre gene and CA-ErbB2 (out of 39 generated, data not shown). Moreover, surviving Fgfr3-iCre+/CA-ErbB2+ mice were small, sickly, and hairless, with wrinkled skin (not shown).
| Supernumerary MYO7+ cells in vivo consequent to ERBB2 activation
In our analyses of P8 and P14 mice, we were surprised to discover many supernumerary Myosin7+ (MYO7+) cells located in the supporting cell regions of CA-ERBB2 cochleae ( Figure 6 ). Mice harbouring Fgfr3-iCre/ROSAflox-rtTA (control) transgenes had normal complements of hair cells, identified with antibodies against MYO7a and Oncomodulin (OCM), juxtaposed to GFP-containing CRE+ cells (Figure 6a,b) . Normal organization was observed in both the mid-base (Figure 6a ) and apical regions (Figure 6b ). Animals additionally harbouring a CA-ErbB2 transgene, in contrast, had supernumerary MYO7+ cells that co-expressed OCM, suggesting outer hair cell differentiation (Figure 6c ,d yellow arrows). Such cells were present in the mid-base turn (Figure 6c , arrows) and in apical regions (Figure 6d, arrow) . Occasionally, supernumerary MYO7+ cells near inner hair cells were also observed in the apical regions (Figure 6e , arrow). Supernumerary MYO7+ cells also expressed another hair cell marker, Parvalbumin (PVALB) (Figure 6e , cyan). They did not express the supporting cell marker SOX2 (Figure 6f , cyan, arrow). They were typically located near GFP+ cells (Figure 6c, d , cf. red with green) but did not express GFP. We quantified supernumerary MYO7+ cells (Figure 6g-i) . Supernumerary MYO7+ cells were readily observed in the supporting cell layer in blinded confocal stacks, as indicated with yellow arrows (Figure 6g,h) . The frequency of supernumerary MYO7+ cells near outer hair cells ranged from 10 to 30 cells/mm of cochlea, to a maximum of 117 total new MYO7+ cells in one organ (Figure 6i ). Few supernumerary cells were observed in control animals (Figure 6i) , and the increase was statistically significant (T con = 0.73, T CA = 13.7, p = 0.018, n = 4 per genotype, student's two-tailed t test). These data suggest that ERBB2 signaling is upstream of a short-range paracrine signal that drives the initial events of hair cell differentiation in young animals in vivo.
| Small molecules that activate ERBB2 pathway promote supporting cell expansion and supernumerary MYO7+ cell generation
Our findings with the conditional ERBB2 activation animal models have shown that the constitutive activation of ERBB2 can result in supporting cell expansion and ectopic MYO7+ cell generation. To further validate the crucial role of ERBB2 activation, we turned to small molecules to pharmacologically activate the EGFR family pathway and determine their effect on supporting cell expansion and hair cell differentiation. Two compounds, WS3 and WS6, were chosen, as these two analogues promoted cell proliferation in growth arrested cells such as islet β cells and retinal pigment epithelial cells Swoboda et al., 2013) . Through their action on ERBB3 binding protein 1 (EBP1/ PA2G4), a component of the EGFR family signaling pathway, these compounds reduced the anti-proliferative role of EBP1 and up-regulated several cell cycle-activated genes Squatrito, Mancino, Donzelli, Areces, & Draetta, 2004; Swoboda et al., 2013) . To test the effect of these drugs on supporting cells, we applied them to cochlear explants derived from Atoh1-nGFP reporter mice, in which hair cells express nuclear GFP (Lumpkin et al., 2003) . With WS3 or WS6 treatment, additional Atoh1-nGFP-positive cells near outer hair cells were seen (Figure 7a and B; F = 3.9, p = 0.0076, ANOVA). The effect was concentrated in the apex, where the number of MYO7+ cells in the apex was increased by 20 cells/100 μm (apex: T con = 53.9, T WS6 = 75.1, T WS3 = 73.8, P WS6 = 0.0024, P WS3 = 0.010; mid-apex: T con = 56.2, T WS6 = 65.4, T WS3 = 72.7, P WS6 = 0.13, P WS3 = 0.046; Mid-base: T con = 59.2, T WS6 = 59.1, T WS3 = 70.8, P WS6 = 0.99, P WS3 = 0.042; n = 3 per group, Dunnett multiple comparisons).
To determine if the drug treatments promoted supporting cell proliferation, we applied them to cochlear explants from wild-type mice at P1-P2 with EdU present to label the proliferating cells. A large number of EdU + cells were observed in the SOX2 + supporting cell region in both WS3 and WS6-treated cochleae (Figure 8a ,b; F = 13.0, p = 0.0000016, ANOVA), with a gradient from apex to base (apex: T con = 4.1, T WS6 = 22.9, T WS3 = 29.0, P WS6 = 0.011, P WS3 = 0.00059; mid-apex: T con = 3.0, T WS6 = 14.8, T WS3 = 17.4, P WS6 = 0.00057, P WS3 = 0.00077; Midbase: T con = 0.85, T WS6 = 6.2, T WS3 = 7.7, P WS6 = 0.0098, P WS3 = 0.0049; n = 3 per group, Dunnett multiple comparisons). These results were consistent with the enhanced supporting cell proliferation observed with the CA-ErbB2 viral transduction in vitro (Figure 2 ). To confirm that the effect of the drugs was mediated through ERBB2 activation, the ERBB2 phosphorylation was analyzed using the protein lysates from cochlear explant. Due to the limited protein quantity from the primary tissue, we were not able to detect the ERBB2 protein signal by Western blot (data not shown); in the breast cancer cell line MCF-7, however, p-ERBB2 level was elevated in response to drug treatment (Figure 8c ), indicating that the ERBB2 signaling pathway was activated by WS3 or WS6. The data suggest that pharmacological activation of EGFR family signaling by small molecules promoted supporting cell proliferation and increased MYO7+ cell generation in vitro, similar to what we had observed in 
| DISCUSSION
The mammalian cochlea lacks the regenerative capacity of non-mammalian counterparts. Here we test intrinsic ERBB2 signaling as a candidate regulator of mammalian cochlear regeneration. We find that neonatal mouse supporting cells expressing a constitutively activated ERBB2 receptor (CA-ERBB2) promote supporting cell proliferation in vitro. Moreover, cochleae with CA-ERBB2 expression develop supernumerary MYO7+ cells in vivo. Both proliferation and MYO7+ induction are observed when small molecule effectors stimulate ERBB3 signaling in vitro. These data suggest ERBB2 signaling as a candidate pathway in regulating the regeneration response. Our findings are summarized in Figure 9 . Each method used to modulate EGFR family signaling had similar, but not identical results. The use of the virus or transgenic technology to drive CA-ERBB2 activity enabled lineage tracing of transduced cells (dark green). Strikingly, we find that it is the cells nearby these transduced cells that respond, either by modulating SOX2 expression (cyan), proliferating (red), or inducing MYO7 (white). That ERBB2 signaling is noncell autonomous implies the existence of downstream signals that regulate these activities, a completely unexpected result. SOX2 modulation was observed with CA-ERBB2 expression both in vitro (Figures 2 and 3 ) and in vivo (Figure 4-6 ), but not after ERBB2/ERBB3 activation with small molecules. Similarly, proliferation was observed with both in vitro systems, but not in vivo. This finding suggests that additional constraints provided by cochlear structure in vivo could play a role in preventing proliferation, for example by limiting cell growth. Finally, we observed significant levels of MYO7 induction in the two systems where it could be assessed. Although not shown here, in preliminary experiments we found that infected cochlear explants became too disorganized and spread out to accurately quantify MYO7+ cells within two days of viral transduction (Figure 9 , "Not assayed"). Importantly, we observe supernumerary MYO7+ cells throughout the cochlea in vivo (Figure 6 ). This rules out the possibility that ERBB2 activation affects secondary processes such as convergent extension. Convergent extension is complete in the basal and middle cochlea by birth (Chen, Johnson, Zoghbi, & Segil, 2002) , when ERBB2 activation is initiated. In concert, these findings strongly implicate EGFR family signaling in the regulation of cochlear regeneration events.
We note that each CA-ErbB2 transgene used in this study was derived from carcinoma cells (Li et al., 2004; Xie et al., 1999) . In many tumours, CA-ERBB2 acts cell-autonomously to promote proliferation. Surprisingly, constitutively active ERBB2 signaling in certain non-proliferating tumour cells drives a change in their secretome that promotes neighbouring cells to change fate and become metastatic (Angelini et al., 2013) . Our data strongly imply that CA-ERBB2 triggers expression of regenerative signals for responding neighbour cells, which parallels the second mechanism. Recently, others have investigated heart regeneration using this CA-ERBB2 transgene (D'Uva et al., 2015) . Transient induction of CA-ERBB2 following myocardial ischaemic injury can improve heart function, by the proliferation and de-differentiation of cardiomyocytes via β-CATENIN accumulation (D'Uva et al., 2015) . Findings in both mammalian cochlear and heart regeneration suggest CA-ERBB2 is driving specific regeneration activities rather than oncogenic transformation.
We report that SOX2 protein expression is reduced in both proliferating and trans-differentiating supporting cells after ErbB2 transduction (Figures 2-6 ). Our proliferation data are consistent with reports that SOX2 directly activates Cdkn1b, a cell cycle inhibitor in supporting cells. Targeted deletion of Sox2 in post-mitotic supporting cells leads to inner pillar cell (a subtype of supporting cell) proliferation . During development, ectopic expression of SOX2 can drive both supporting cell and hair cell markers (Pan et al., 2013; Puligilla & Kelley, 2017) . SOX2 binds to the Atoh1 promoter and increases its expression levels (Kempfle, Turban, & Edge, 2016; Neves, Uchikawa, Bigas, & Giraldez, 2012; Puligilla & Kelley, 2017) . Interestingly, SOX2 also drives expression of ATOH1 repressors, including Hes genes and Id1 (Neves, Vachkov, & Giraldez, 2013; Neves et al., 2012) . In this so-called incoherent feed-forward loop (Alon, 2007) , such contradictory effects of the inducer SOX2 drive a pulselike accumulation of the target, ATOH1, which is sufficient for hair cell differentiation (Zheng & Gao, 2000) . Our data support the model that prolonged SOX2 expression may maintain the post-mitotic supporting cell phenotype.
Recent efforts from other laboratories describe potential candidates for CA-ERBB2's as yet unknown downstream signal. Supernumerary hair cells are observed when NOTCH1 signaling is reduced in supporting cells (Lanford et al., 1999; Mizutari et al., 2013; Yamamoto et al., 2006) . As NOTCH signaling maintains SOX2 expression in supporting cells during the neonatal period (Kiernan, Xu, & Gridley, 2006; Lanford et al., 1999; Pan et al., 2013) , this pathway fits well with our data. Stabilization of the WNT effector β-CATENIN in neonatal supporting cells promotes their proliferation (Chai et al., 2012; Kuo, Baldwin, Layman, Taketo, & Zuo, 2015; Shi, Hu, & Edge, 2013) . This treatment also increases Atoh1 expression, likely through direct interactions of β-CATENIN with the Atoh1 enhancer (Shi, Cheng, Wang, & Edge, 2010) . SHH treatment also promotes rodent supporting cell proliferation in vitro (Lu et al., 2013) . ERBB2 binds to other EGFR family proteins and various receptor tyrosine kinases (Jones, Gordus, Krall, & MacBeath, 2006) . ERBB2 heterodimers with other EGFR family proteins are the active receptors for growth factor ligands and amplify EGFR family signaling by slowing endocytosis and decreasing the receptor-recycling period [reviewed in (Bertelsen & Stang, 2014) ]. This would enhance the existing growth factor signaling in our CA-ERBB2 model. Further experiments will be required to determine which of these pathways may act downstream of CA-ERBB2. Further experiments will also be necessary to determine if there is heterogeneity in the responses of supporting cells to intrinsic CA-ERBB2 signaling, which supporting cells produce factors to induce regeneration-like responses, if regeneration-like responses have a concentration dependence, and if inhibitor molecules that limit the scope of regeneration are also produced.
In addition to investigating ERBB2 in transgenic models, we identify two small molecules, WS6 and WS3, that exhibited similar regenerative potential by regulating ERBB2 signaling (Figures 7 and 8 ). WS6 treatment increases β-cell mass in a rodent diabetes model by promoting cell proliferation , while WS3 expands retinal pigment epithelium cells and preserves vision when the cells are transplanted into a retinal degeneration model (Swoboda et al., 2013) . Here we assess the effects of WS6 and WS3 in cochlear explant culture. While WS6 and WS3 activate ERBB2 in MCF-7 cells (Figure 8 ), we could not confirm this activation in the cochlear culture. Besides direct activation of ERBB2 phosphorylation, these two EBP1 inhibitors may alter the EGFR family signaling cascade through other means. EBP1/PA2G4 is expressed throughout the sensory region of the P0 mouse cochlea (Hertzano & Orvis, 2016) . EBP1 negatively regulates ERBB2 mRNA and protein level via transcriptional mechanisms (Ghosh, Awasthi, & Hamburger, 2013) . A recent study showed that EBP1 interacts with the EGFR family downstream molecule PI3K and inhibits its kinase activity (Ko et al., 2014) . Our EBP1 inhibitor might increase PI3K activity and enhance the EGFR family signaling. Our results provide a potential approach using drugs to enhance hair cell regeneration in future studies.
We note that during normal cochlear homeostasis, EGFR family signaling is implicated in the regulation of spiral ganglion neuron innervation. The expression of a dominant negative ERBB2 variant in supporting cells shows that this signaling is crucial for the survival of spiral ganglion neurons (Stankovic et al., 2004) . How then, can EGFR family signaling be tasked with two completely separate functions: regeneration and innervation? The intracellular signaling sites on ERBB2 are highly promiscuous, strongly interacting with at least 17 distinct protein domains (Jones et al., 2006) . We speculate that mammalian supporting cells may express different levels of specific EGFR family interactants compared to bird or fish supporting cells. Our work implicates EBP1, a regulator of ERBB2/ERBB3 signaling, in blocking supporting cell regeneration activities. It is possible that evolution may have redirected EGFR family signaling in mammals towards facilitating innervation and away from regeneration.
In summary, we demonstrate a potential role of EGFR family signaling in stimulating supporting cell proliferation and supernumerary MYO7+ cell differentiation in neonatal mouse cochlea. Using multiple methods to activate EGFR family signaling, we find that its constitutive activation promotes regeneration processes in neighbouring supporting cells. Taken together with ERBB2's role in detecting stretch damage in other epithelial tissues, our findings suggest that within some supporting cells, EGFR family signaling may initiate a cascade of downstream signaling pathways that enhance regeneration activity.
